None listed
Conditions
Interventions
Drug : During the five-year study intervention period, thyroid hormone (oral administration) supplementary doses are determined according to a dose-adjustment protocol established for each group's tar
Sponsors
Seoul National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Patients with histological confirmation of papillary thyroid cancer* * Papillary thyroid cancer (TNM(tumor, node, and metastasis) stage is evaluated according to the 8th edition of AJCC(American Joint Committee on Cancer)/UICC(The Union for International Cancer Control) TNM(tumor, node, and metastasis) staging system (2017)) -Maximum tumor diameter = 4 cm -Extrathyroidal extension: No invasion of adjacent organs(nerves, vascular, trachea, etc) -Node stage: Clinical N0, N1a • Patients who will receive thyroid lobectomy, or who received thyroid lobectomy within previous 3 weeks • Non-pregnant women of childbearing potential (confirmed by medical history taking) • Ages 19 to 80 (less than 80) • If there are nodules in the opposite lobe: Thyroid nodules are evaluated by ultrasound (based on K-TIRADS(Korean Thyroid Imaging Reporting and Data System)). Bethesda classification criteria 1-3 if the fine needle aspiration test is indicated
Exclusion criteria
Exclusion criteria: • The following patients in the postoperative findings -pT4, pN1b or M1 - PTC with Aggressive histological features : diffuse sclerosing variant -Other types of thyroid cancer (follicular, poorly differentiated, anaplastic, or medullary thyroid cancer) • Completion thyroidectomy is required • Residual disease present(R1/ R2 resection) • No proper evaluation of nodules located in the contralateral lobe, or Bethesda classification criteria 4-6 in the result of fine needle aspiration test • Hyperthyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival;Disease specific survival;Target-TSH-level achievement rate;The incidence of cardiovascular and metabolic complications (cardiovascular disease, Arrhythmia, hypercholesterolemia, fatty liver, etc.);The incidence of musculoskeletal complications (fracture, bone density reduction, sarcopenia);The incidence of psychiatric complications (lower quality of life, affective disorder, etc.);Cost analysis (related medical expenses, loss of productivity);predictors of recurrence;predictors of cardiovascular complications;predictors of musculoskeletal complications;predictors of psychiatric complications;predictors of TSH levels and proper thyroid hormone dosage;Genetic susceptibility (Consider secondary analysis);Test interval for efficient diagnosis of recurrence | — |
Countries
Korea, Republic of
Contacts
Public ContactEunKyung Lee
National Cancer Center
Outcome results
None listed